Aardvark Therapeutics focuses on developing small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics, Inc. is a biopharmaceutical company in the clinical stage that is dedicated to the advancement and marketing of small molecule therapeutics activating intrinsic homeostatic pathways to treat illnesses. The primary product, ARD-101, is an innovative oral formulation that is restricted to the gut but induces systemic effects by stimulating secretion of gut peptide hormones. Preclinical studies have shown its safety and effectiveness in various models of metabolic and inflammatory diseases.